Tenofovir, equivalence, and noninferiority.
作者信息
Parienti Jean-Jacques
出版信息
JAMA. 2004 Oct 27;292(16):1951; author reply 1951-2. doi: 10.1001/jama.292.16.1951-a.
PMID:15507576
Abstract
摘要
相似文献
1
Tenofovir, equivalence, and noninferiority.
JAMA. 2004 Oct 27;292(16):1951; author reply 1951-2. doi: 10.1001/jama.292.16.1951-a.
2
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA. 2004 Jul 14;292(2):191-201. doi: 10.1001/jama.292.2.191.
3
Tenofovir ready for approval.
AIDS Patient Care STDS. 2001 Jul;15(7):399. doi: 10.1089/108729101750301951.
4
From the Food and Drug Administration.
JAMA. 2001 Dec 5;286(21):2660.
5
Tenofovir-related nephrotoxicity in HIV-infected patients.
AIDS. 2004 Apr 9;18(6):960-3. doi: 10.1097/00002030-200404090-00019.
6
Tenofovir disoproxil fumarate.
Drugs. 2003;63(15):1609-10. doi: 10.2165/00003495-200363150-00008.
7
Tenofovir disoproxil fumarate.
Drugs. 2003;63(15):1609-10. doi: 10.2165/00003495-200363150-00007.
8
Summaries for patients. Treatment for resistant HIV-1 infection.
Ann Intern Med. 2003 Sep 2;139(5 Pt 1):I22. doi: 10.7326/0003-4819-139-5_part_1-200309020-00001.
9
Tenofovir gel studied.
AIDS Patient Care STDS. 2002 Aug;16(8):401-2. doi: 10.1089/10872910260196431.
10
[Further indications for tenofovir].
Dtsch Med Wochenschr. 2003 Sep 26;128(39):2037.
引用本文的文献
1
Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance.
BMC Med Res Methodol. 2006 Sep 20;6:46. doi: 10.1186/1471-2288-6-46.
Zotero 插件